CB 1-independent mechanisms of Δ 9-THCV, AM251 and SR141716 (rimonabant)

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 260-265

  Raffa, R B ^a   Ward, S J ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

9 THCV; AM251; cannabinoid; CB 1 receptors; rimonabant; SR141716

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AM 4113; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; DELTA8 TETRAHYDROCANNABINOL DERIVATIVE; DELTA9 TETRAHYDROCANNABIVARIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG;

ANXIETY DISORDER; BASAL GANGLION; BRAIN TISSUE; CEREBELLUM; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; NERVE CELL MEMBRANE; NEUROPROTECTION; NONHUMAN; RECEPTOR AFFINITY; RESTLESSNESS; REVIEW; SLEEP DISORDER; SYSTEMATIC REVIEW;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; HUMANS; LIGANDS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; TETRAHYDROCANNABINOL;

EID: 84861336596     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01284.x     Document Type: Review

References (54)

1. Xie S, Furjanic MA, Ferrara JJ, et al. (2007) The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. Journal of Clinical Pharmacy and Therapeutics, 32, 209-231.
2. Fong TM, Heymsfield SB, (2009) Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. International Journal of Obesity, 33, 947-955.
3. Janero DR, Makriyannis A, (2009) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs, 14, 43-65.
4. Jesudason D, Wittert G, (2008) Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology, 19, 344-348.
5. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A, (2008) Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiology and Behavior, 93, 666-670.
6. Tucci SA, Halford JC, Harrold JA, Kirkham TC, (2006) Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Current Medicinal Chemistry, 13, 2669-2680.
7. Lange JH, Kruse CG, (2005) Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discovery Today, 10, 693-702.
8. Vickers SP, Kennett GA, (2005) Cannabinoids and the regulation of ingestive behaviour. Current Drug Targets, 6, 215-223.
9. Shire D, Calandra B, Bouaboula M, et al. (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sciences, 65, 627-635.
10. Ward SJ, Dykstra LA, (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behavioural Pharmacology, 16, 381-388.
11. Ward SJ, Walker EA, Dykstra LA, (2007) Effect of cannabinoid CB1 receptor antagonist SR141716A and CB1 receptor knockout on cue-induced reinstatement of Ensure and corn-oil seeking in mice. Neuropsychopharmacology, 32, 2592-2600.
12. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC, (1988) Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34, 605-613.
13. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
14. Shire D, Carillon C, Kaghad M, et al. (1995) An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Journal of Biological Chemistry, 270, 3726-3731.
15. Lynn AB, Herkenham M, (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. Journal of Pharmacology and Experimental Therapeutics, 268, 1612-1623.
16. Gerard CM, Mollereau C, Vassart G, Parmentier M, (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal, 279 (Pt 1), 129-134.
17. Ryberg E, Larsson N, Sjogren S, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152, 1092-1101.
18. Howlett AC, (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology, 27, 429-436.
19. Felder CC, Joyce KE, Briley EM, et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology and Experimental Therapeutics, 284, 291-297.
20. Breivogel CS, Childers SR, (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiology of Disease, 5, 417-431.
21. Childers SR, Breivogel CS, (1998) Cannabis and endogenous cannabinoid systems. Drug and Alcohol Dependence, 51, 173-187.
22. Compton DR, Rice KC, De Costa BR, et al. (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. Journal of Pharmacology and Experimental Therapeutics, 265, 218-226.
23. Compton DR, Aceto MD, Lowe J, Martin BR, (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. Journal of Pharmacology and Experimental Therapeutics, 277, 586-594.
24. Dennis I, Whalley BJ, Stephens GJ, (2008) Effects of Delta9- tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes. British Journal of Pharmacology, 154, 1349-1358.
25. Arunlakshana O, Schild HO, (1959) Some quantitative uses of drug antagonists. British Journal of Pharmacology, 14, 48-58.
26. Tallarida RJ, Cowan A, Adler MW, (1979) pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sciences, 25, 637-654.
27. Pertwee RG, (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sciences, 76, 1307-1324.
28. Breivogel CS, Griffin G, Di Marzo V, Martin BR, (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology, 60, 155-163.
29. Cinar R, Szücs M, (2009) CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. Journal of Pharmacology and Experimental Therapeutics, 330, 567-574.
30. Wiley JL, Breivogel CS, Mahadevan A, et al. (2011) Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. European Journal of Pharmacology, 651, 96-105.
31. Pickel VM, Chan J, Kash TL, Rodriguez JJ, MacKie K, (2004) Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience, 127, 101-112.
32. Waldhoer M, Bartlett SE, Whistler JL, (2004) Opioid receptors. Annual Reviews of Biochemistry, 73, 953-990.
33. Rios C, Gomes I, Devi LA, (2006) mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. British Journal of Pharmacology, 148, 387-395.
34. Canals M, Milligan G, (2008) Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. Journal of Biological Chemistry, 283, 11424-11434.
35. Childers SR, (1991) Opioid receptor-coupled second messenger systems. Life Sciences, 48, 1991-2003.
36. Szücs M, Boda K, Gintzler AR, (2004) Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen- Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling. Journal of Pharmacology and Experimental Therapeutics, 310, 256-262.
37. Chakrabarti S, Regec A, Gintzler AR, (2005) Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure. Brain Research (Molecular Brain Research), 135, 217-224.
38. Sink KS, Segovia KN, Sink J, et al. (2010) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. European Neuropsychopharmacology, 20, 112-122.
39. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R, (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27, 73-100.
40. Rinaldi-Carmona M, Calandra B, Shire D, et al. (1996) Characterization of two cloned human CB1 cannabinoid receptor isoforms. Journal of Pharmacology and Experimental Therapeutics, 278, 871-878.
41. Tzavara ET, Davis RJ, Perry KW, et al. (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology, 138, 544-553.
42. Pertwee RG, (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Current Medicinal Chemistry, 17, 1360-1381.
43. Verty AN, Boon WM, Mallet PE, McGregor IS, Oldfield BJ, (2009) Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). European Journal of Neuroscience, 29, 2207-2216.
44. Schiöth HB, (2006) G protein-coupled receptors in regulation of body weight. CNS & Neurological Disorders Drug Targets, 5, 241-249.
45. Hilairet S, Bouaboula M, Carrière D, Le Fur G, Casellas P, (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. Journal of Biological Chemistry, 278, 23731-23737.
46. Crespo I, Gómez de Heras R, Rodríguez de Fonseca F, Navarro M, (2008) Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology, 54, 219-225.
47. Sim-Selley LJ, Brunk LK, Selley DE, (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. European Journal of Pharmacology, 414, 135-143.
48. Pertwee RG, Howlett AC, Abood ME, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacological Reviews, 62, 588-631.
49. Begg M, Pacher P, Bátkai S, et al. (2005) Evidence for novel cannabinoid receptors. Pharmacology & Therapeutics, 106, 133-145.
50. Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT, (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. British Journal of Pharmacology, 140, 1451-1459.
51. Gibson HE, Edwards JG, Page RS, Van Hook MJ, Kauer JA, (2008) TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron, 57, 746-759.
52. Ward SJ, Walker EA, (2009) Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice. Behavioural Pharmacology, 20, 605-613.
53. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF, (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. European Journal of Neuroscience, 16, 1395-1398.
54. Fride E, Foox A, Rosenberg E, et al. (2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. European Journal of Pharmacology, 461, 27-34.